| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 123 | 2024 | 4863 | 11.150 |
Why?
|
| Venous Thromboembolism | 72 | 2024 | 1882 | 9.280 |
Why?
|
| Thrombosis | 52 | 2024 | 2956 | 8.590 |
Why?
|
| Hemorrhage | 47 | 2024 | 3463 | 4.580 |
Why?
|
| Heparin | 22 | 2024 | 1632 | 4.430 |
Why?
|
| Thrombophilia | 12 | 2021 | 308 | 4.070 |
Why?
|
| Warfarin | 18 | 2024 | 1494 | 3.970 |
Why?
|
| Heart-Assist Devices | 23 | 2024 | 1297 | 3.840 |
Why?
|
| Blood Coagulation Factors | 8 | 2024 | 372 | 3.830 |
Why?
|
| Thromboembolism | 18 | 2024 | 1003 | 3.670 |
Why?
|
| Factor Xa | 8 | 2024 | 166 | 3.200 |
Why?
|
| Thrombocytopenia | 12 | 2023 | 1171 | 2.940 |
Why?
|
| International Normalized Ratio | 11 | 2024 | 381 | 2.710 |
Why?
|
| Blood Coagulation | 22 | 2024 | 1168 | 2.670 |
Why?
|
| Blood Coagulation Disorders | 13 | 2024 | 350 | 2.660 |
Why?
|
| Venous Thrombosis | 13 | 2024 | 1327 | 2.590 |
Why?
|
| Fibrinolytic Agents | 17 | 2024 | 2082 | 2.450 |
Why?
|
| Pregnancy Complications, Hematologic | 10 | 2021 | 184 | 2.370 |
Why?
|
| Pyridones | 17 | 2024 | 816 | 2.340 |
Why?
|
| Neoplasms | 44 | 2024 | 22350 | 2.290 |
Why?
|
| Heparin, Low-Molecular-Weight | 13 | 2024 | 345 | 2.000 |
Why?
|
| Vitamin K | 7 | 2024 | 312 | 2.000 |
Why?
|
| Nomograms | 5 | 2024 | 235 | 1.960 |
Why?
|
| Recombinant Proteins | 12 | 2024 | 6489 | 1.660 |
Why?
|
| Blood Coagulation Tests | 10 | 2021 | 263 | 1.630 |
Why?
|
| Pyrazoles | 16 | 2024 | 2031 | 1.620 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2024 | 1480 | 1.590 |
Why?
|
| Antidotes | 5 | 2019 | 138 | 1.540 |
Why?
|
| Pulmonary Embolism | 16 | 2022 | 2600 | 1.470 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 4 | 2024 | 245 | 1.440 |
Why?
|
| Dalteparin | 8 | 2024 | 44 | 1.400 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 13 | 2022 | 428 | 1.360 |
Why?
|
| von Willebrand Diseases | 6 | 2024 | 135 | 1.340 |
Why?
|
| Administration, Oral | 26 | 2024 | 4015 | 1.340 |
Why?
|
| Premedication | 3 | 2019 | 245 | 1.330 |
Why?
|
| Disseminated Intravascular Coagulation | 8 | 2024 | 185 | 1.300 |
Why?
|
| Hirudins | 4 | 2017 | 179 | 1.250 |
Why?
|
| Humans | 326 | 2024 | 766011 | 1.210 |
Why?
|
| Hemostasis | 8 | 2024 | 467 | 1.140 |
Why?
|
| Antithrombins | 9 | 2023 | 295 | 1.120 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 3099 | 1.120 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 3222 | 1.100 |
Why?
|
| Hodgkin Disease | 20 | 2017 | 1383 | 1.030 |
Why?
|
| Platelet Aggregation Inhibitors | 13 | 2024 | 2771 | 1.000 |
Why?
|
| Hemostatics | 5 | 2023 | 247 | 1.000 |
Why?
|
| Partial Thromboplastin Time | 8 | 2024 | 202 | 0.990 |
Why?
|
| Myeloproliferative Disorders | 3 | 2024 | 615 | 0.990 |
Why?
|
| Hematologic Neoplasms | 5 | 2021 | 1927 | 0.980 |
Why?
|
| Atrial Fibrillation | 10 | 2024 | 5188 | 0.910 |
Why?
|
| Recurrence | 21 | 2024 | 8505 | 0.900 |
Why?
|
| Drug Monitoring | 4 | 2019 | 961 | 0.860 |
Why?
|
| Factor XI Deficiency | 2 | 2021 | 16 | 0.850 |
Why?
|
| Vaccines | 2 | 2022 | 841 | 0.850 |
Why?
|
| Atrial Flutter | 2 | 2024 | 253 | 0.790 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 17 | 2015 | 1435 | 0.780 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2024 | 166 | 0.770 |
Why?
|
| Blood Component Transfusion | 2 | 2019 | 138 | 0.770 |
Why?
|
| Aspirin | 8 | 2023 | 3135 | 0.770 |
Why?
|
| Peptide Fragments | 4 | 2017 | 5123 | 0.730 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2024 | 1560 | 0.710 |
Why?
|
| Pandemics | 16 | 2024 | 8699 | 0.690 |
Why?
|
| Hematology | 2 | 2023 | 243 | 0.690 |
Why?
|
| Vasculitis | 2 | 2021 | 523 | 0.680 |
Why?
|
| Hemophilia B | 2 | 2023 | 83 | 0.680 |
Why?
|
| Muscular Diseases | 1 | 2024 | 550 | 0.670 |
Why?
|
| Hemophilia A | 3 | 2023 | 357 | 0.670 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2018 | 27 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 11862 | 0.650 |
Why?
|
| Drug Resistance | 2 | 2024 | 1591 | 0.640 |
Why?
|
| Weightlessness | 1 | 2020 | 103 | 0.640 |
Why?
|
| Blood Platelet Disorders | 1 | 2019 | 59 | 0.640 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2020 | 187 | 0.640 |
Why?
|
| Perioperative Care | 3 | 2024 | 1056 | 0.630 |
Why?
|
| Chemoprevention | 1 | 2021 | 327 | 0.630 |
Why?
|
| Pyridines | 5 | 2021 | 2889 | 0.630 |
Why?
|
| Janus Kinase 2 | 2 | 2021 | 562 | 0.630 |
Why?
|
| Sex Reassignment Procedures | 1 | 2019 | 72 | 0.620 |
Why?
|
| Designer Drugs | 1 | 2018 | 21 | 0.620 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 631 | 0.610 |
Why?
|
| Stroke | 9 | 2024 | 9750 | 0.590 |
Why?
|
| Heart Failure | 13 | 2024 | 11839 | 0.590 |
Why?
|
| Blood Group Incompatibility | 1 | 2018 | 134 | 0.580 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2018 | 72 | 0.580 |
Why?
|
| Hemoptysis | 1 | 2019 | 150 | 0.580 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2018 | 132 | 0.570 |
Why?
|
| Risk Adjustment | 1 | 2021 | 596 | 0.570 |
Why?
|
| Middle Aged | 112 | 2024 | 223058 | 0.570 |
Why?
|
| Benzamides | 4 | 2021 | 1376 | 0.570 |
Why?
|
| Risk Factors | 50 | 2024 | 74870 | 0.560 |
Why?
|
| Female | 139 | 2024 | 396159 | 0.560 |
Why?
|
| Space Flight | 1 | 2020 | 219 | 0.560 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 246 | 0.560 |
Why?
|
| Male | 131 | 2024 | 363808 | 0.550 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 380 | 0.540 |
Why?
|
| Plasma | 2 | 2019 | 579 | 0.530 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2024 | 1127 | 0.530 |
Why?
|
| Tranexamic Acid | 1 | 2019 | 174 | 0.520 |
Why?
|
| Formularies as Topic | 1 | 2016 | 93 | 0.520 |
Why?
|
| beta-Alanine | 2 | 2014 | 83 | 0.520 |
Why?
|
| Cannabinoids | 1 | 2018 | 174 | 0.520 |
Why?
|
| Extracorporeal Circulation | 1 | 2016 | 182 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 10389 | 0.510 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 206 | 0.510 |
Why?
|
| Testicular Neoplasms | 2 | 2020 | 802 | 0.500 |
Why?
|
| Transsexualism | 1 | 2019 | 210 | 0.500 |
Why?
|
| Factor VII Deficiency | 1 | 2015 | 31 | 0.500 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 484 | 0.490 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 704 | 0.490 |
Why?
|
| Aged | 76 | 2024 | 171233 | 0.470 |
Why?
|
| Adult | 96 | 2024 | 223109 | 0.460 |
Why?
|
| Asparaginase | 4 | 2024 | 240 | 0.460 |
Why?
|
| Factor XI | 3 | 2024 | 40 | 0.460 |
Why?
|
| von Willebrand Factor | 4 | 2024 | 676 | 0.440 |
Why?
|
| Intracranial Hemorrhages | 2 | 2018 | 814 | 0.440 |
Why?
|
| Vincristine | 21 | 2015 | 1038 | 0.430 |
Why?
|
| Retrospective Studies | 43 | 2024 | 81522 | 0.430 |
Why?
|
| Risk Assessment | 16 | 2024 | 24299 | 0.430 |
Why?
|
| Benzimidazoles | 3 | 2014 | 863 | 0.430 |
Why?
|
| Abortion, Habitual | 1 | 2014 | 65 | 0.430 |
Why?
|
| Fibrinogen | 3 | 2022 | 897 | 0.420 |
Why?
|
| Thiazoles | 2 | 2023 | 1529 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 7 | 2018 | 9244 | 0.420 |
Why?
|
| Fibrinolysis | 3 | 2024 | 332 | 0.420 |
Why?
|
| Emergencies | 1 | 2019 | 1224 | 0.410 |
Why?
|
| Epidemics | 1 | 2018 | 513 | 0.410 |
Why?
|
| Physician's Role | 1 | 2019 | 927 | 0.400 |
Why?
|
| Prostate | 1 | 2021 | 1759 | 0.400 |
Why?
|
| British Columbia | 11 | 2017 | 238 | 0.400 |
Why?
|
| Vascular Diseases | 1 | 2020 | 1164 | 0.390 |
Why?
|
| Drug Costs | 2 | 2019 | 1193 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 11 | 2022 | 7426 | 0.380 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 3674 | 0.370 |
Why?
|
| Antifibrinolytic Agents | 3 | 2020 | 286 | 0.370 |
Why?
|
| Prednisone | 20 | 2015 | 1563 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2018 | 5753 | 0.360 |
Why?
|
| Outpatients | 4 | 2022 | 1593 | 0.360 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3803 | 0.360 |
Why?
|
| Gingival Hemorrhage | 2 | 2009 | 49 | 0.360 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2017 | 844 | 0.360 |
Why?
|
| Immunologic Factors | 3 | 2018 | 1585 | 0.350 |
Why?
|
| Doxorubicin | 22 | 2017 | 2229 | 0.350 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 500 | 0.350 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2008 | 1376 | 0.340 |
Why?
|
| Treatment Outcome | 38 | 2024 | 65236 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 3251 | 0.330 |
Why?
|
| Cyclophosphamide | 22 | 2015 | 2226 | 0.330 |
Why?
|
| Hemosiderosis | 1 | 2010 | 66 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 5528 | 0.330 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 1287 | 0.330 |
Why?
|
| Disease Management | 6 | 2021 | 2534 | 0.320 |
Why?
|
| Drug Approval | 1 | 2016 | 818 | 0.320 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2335 | 0.320 |
Why?
|
| Platelet Count | 6 | 2023 | 782 | 0.310 |
Why?
|
| Ambulatory Care | 3 | 2018 | 2778 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 6 | 2022 | 1056 | 0.310 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 1175 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 1404 | 0.300 |
Why?
|
| Heart Transplantation | 3 | 2017 | 3310 | 0.300 |
Why?
|
| Prognosis | 30 | 2021 | 29915 | 0.300 |
Why?
|
| Labor, Obstetric | 1 | 2011 | 316 | 0.290 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 6307 | 0.290 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 2465 | 0.290 |
Why?
|
| Bleomycin | 13 | 2017 | 491 | 0.290 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 59526 | 0.290 |
Why?
|
| Pregnancy | 17 | 2022 | 30253 | 0.280 |
Why?
|
| Registries | 6 | 2021 | 8321 | 0.280 |
Why?
|
| Mediastinal Neoplasms | 2 | 2009 | 403 | 0.270 |
Why?
|
| Delivery, Obstetric | 2 | 2011 | 946 | 0.270 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2024 | 1090 | 0.260 |
Why?
|
| Lymphoma, B-Cell | 6 | 2005 | 943 | 0.260 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 8040 | 0.250 |
Why?
|
| Combined Modality Therapy | 22 | 2016 | 8531 | 0.250 |
Why?
|
| Enoxaparin | 2 | 2020 | 390 | 0.240 |
Why?
|
| Critical Care | 5 | 2024 | 2712 | 0.240 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 13455 | 0.240 |
Why?
|
| Leukemia, Hairy Cell | 4 | 1998 | 82 | 0.240 |
Why?
|
| Drug Administration Schedule | 9 | 2020 | 4850 | 0.230 |
Why?
|
| Markov Chains | 2 | 2019 | 967 | 0.230 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 2136 | 0.230 |
Why?
|
| Anesthesia, Obstetrical | 2 | 2021 | 246 | 0.230 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2024 | 29 | 0.230 |
Why?
|
| Secondary Prevention | 2 | 2021 | 1471 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2021 | 1168 | 0.220 |
Why?
|
| Prospective Studies | 18 | 2024 | 54818 | 0.220 |
Why?
|
| Hospitalization | 7 | 2023 | 10807 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 12 | 2000 | 2729 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 1083 | 0.210 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 2067 | 0.210 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2024 | 136 | 0.210 |
Why?
|
| Syndrome | 3 | 2022 | 3269 | 0.210 |
Why?
|
| Postoperative Hemorrhage | 2 | 2018 | 413 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2004 | 125 | 0.210 |
Why?
|
| Lymphoma | 7 | 1997 | 1897 | 0.210 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 5196 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5336 | 0.200 |
Why?
|
| Disease-Free Survival | 11 | 2017 | 6838 | 0.200 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2017 | 238 | 0.200 |
Why?
|
| Heart Ventricles | 4 | 2019 | 3831 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 10731 | 0.190 |
Why?
|
| Sepsis | 3 | 2022 | 2602 | 0.190 |
Why?
|
| Antithrombin III Deficiency | 1 | 2021 | 28 | 0.190 |
Why?
|
| Incidence | 12 | 2024 | 21507 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 1739 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 9371 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 411 | 0.180 |
Why?
|
| Endothelium, Vascular | 3 | 2024 | 4423 | 0.180 |
Why?
|
| Transplantation, Autologous | 8 | 2014 | 2126 | 0.180 |
Why?
|
| Disease Progression | 7 | 2024 | 13615 | 0.170 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 1669 | 0.170 |
Why?
|
| Prothrombin Time | 1 | 2020 | 116 | 0.170 |
Why?
|
| Foramen Ovale, Patent | 1 | 2023 | 211 | 0.170 |
Why?
|
| Neoplasm Staging | 13 | 2019 | 11208 | 0.170 |
Why?
|
| Transplantation, Homologous | 9 | 2018 | 4858 | 0.170 |
Why?
|
| Academic Medical Centers | 4 | 2018 | 2780 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 2973 | 0.170 |
Why?
|
| Patients | 2 | 2023 | 910 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2010 | 1939 | 0.160 |
Why?
|
| Antineoplastic Agents | 9 | 2021 | 13639 | 0.160 |
Why?
|
| Thiophenes | 1 | 2023 | 570 | 0.160 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 114 | 0.160 |
Why?
|
| Communication | 2 | 2024 | 3913 | 0.160 |
Why?
|
| Etoposide | 10 | 2005 | 636 | 0.160 |
Why?
|
| Geriatrics | 1 | 2023 | 395 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2020 | 185 | 0.150 |
Why?
|
| Illinois | 1 | 2018 | 120 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2021 | 297 | 0.150 |
Why?
|
| Plasma Exchange | 2 | 2018 | 160 | 0.150 |
Why?
|
| Live Birth | 2 | 2020 | 518 | 0.150 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2018 | 20 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2023 | 544 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 131 | 0.150 |
Why?
|
| Abortion, Spontaneous | 2 | 2020 | 535 | 0.150 |
Why?
|
| Drug and Narcotic Control | 1 | 2019 | 144 | 0.150 |
Why?
|
| Comorbidity | 6 | 2024 | 10572 | 0.150 |
Why?
|
| Body Weight | 2 | 2019 | 4624 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 2 | 2019 | 2649 | 0.140 |
Why?
|
| Ferritins | 1 | 2020 | 600 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 180 | 0.140 |
Why?
|
| Genes, bcl-2 | 1 | 1997 | 119 | 0.140 |
Why?
|
| Shock | 1 | 2019 | 316 | 0.140 |
Why?
|
| Blood Platelets | 3 | 2023 | 2464 | 0.140 |
Why?
|
| Aneurysm, False | 1 | 2019 | 265 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 86 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 2423 | 0.130 |
Why?
|
| Time Factors | 14 | 2024 | 40117 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 1062 | 0.130 |
Why?
|
| Leucovorin | 5 | 2005 | 641 | 0.130 |
Why?
|
| Clinical Protocols | 4 | 2018 | 1441 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 655 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2019 | 764 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2016 | 272 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 1203 | 0.120 |
Why?
|
| Cesarean Section | 3 | 2021 | 1431 | 0.120 |
Why?
|
| Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 231 | 0.120 |
Why?
|
| Accidents, Traffic | 1 | 2001 | 818 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2019 | 475 | 0.120 |
Why?
|
| Vasodilation | 1 | 2019 | 970 | 0.120 |
Why?
|
| Algorithms | 4 | 2019 | 14061 | 0.120 |
Why?
|
| Patient Selection | 3 | 2021 | 4257 | 0.120 |
Why?
|
| Vinblastine | 6 | 2017 | 483 | 0.120 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 991 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4057 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2019 | 3563 | 0.120 |
Why?
|
| Postoperative Complications | 4 | 2019 | 15803 | 0.120 |
Why?
|
| Factor VIII | 2 | 2023 | 347 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 806 | 0.110 |
Why?
|
| Adolescent | 29 | 2024 | 88804 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2564 | 0.110 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2016 | 214 | 0.110 |
Why?
|
| Extremities | 1 | 2019 | 870 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2018 | 4526 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2018 | 1416 | 0.110 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 1277 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2020 | 1622 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2017 | 493 | 0.110 |
Why?
|
| Stem Cell Transplantation | 2 | 2014 | 1601 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 1999 | 1409 | 0.100 |
Why?
|
| Propensity Score | 1 | 2021 | 1967 | 0.100 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 1110 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2023 | 4521 | 0.100 |
Why?
|
| Legislation, Drug | 1 | 2015 | 216 | 0.100 |
Why?
|
| Leukocytes | 1 | 2021 | 2027 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2024 | 8733 | 0.100 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 2060 | 0.100 |
Why?
|
| Shock, Septic | 1 | 2019 | 772 | 0.100 |
Why?
|
| Nuclear Physics | 1 | 2012 | 73 | 0.100 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 55 | 0.100 |
Why?
|
| Health Resources | 1 | 2019 | 949 | 0.100 |
Why?
|
| Creatinine | 2 | 2016 | 1917 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 595 | 0.100 |
Why?
|
| Young Adult | 9 | 2024 | 59870 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3804 | 0.100 |
Why?
|
| Nitriles | 1 | 2017 | 981 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2019 | 1475 | 0.100 |
Why?
|
| Pharmacists | 1 | 2014 | 261 | 0.100 |
Why?
|
| United States | 9 | 2022 | 72914 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 1194 | 0.100 |
Why?
|
| Forecasting | 1 | 2021 | 2938 | 0.100 |
Why?
|
| Lung Transplantation | 2 | 2018 | 1311 | 0.100 |
Why?
|
| Vaccination | 1 | 2024 | 3425 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2022 | 1172 | 0.100 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2016 | 327 | 0.100 |
Why?
|
| Hematologic Tests | 2 | 2009 | 239 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 961 | 0.100 |
Why?
|
| Neutrophils | 3 | 2021 | 3771 | 0.090 |
Why?
|
| Survival Analysis | 10 | 2020 | 10086 | 0.090 |
Why?
|
| Nurses | 2 | 2018 | 2505 | 0.090 |
Why?
|
| Survival Rate | 14 | 2009 | 12821 | 0.090 |
Why?
|
| Methotrexate | 5 | 2005 | 1721 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2023 | 12433 | 0.090 |
Why?
|
| Leukocyte Transfusion | 3 | 2000 | 58 | 0.090 |
Why?
|
| Aftercare | 3 | 2022 | 914 | 0.090 |
Why?
|
| Age Factors | 5 | 2024 | 18384 | 0.090 |
Why?
|
| Arginine | 2 | 2024 | 933 | 0.090 |
Why?
|
| Ischemia | 1 | 2019 | 1923 | 0.090 |
Why?
|
| Acute Disease | 4 | 2024 | 7238 | 0.090 |
Why?
|
| Thrombopoietin | 2 | 2023 | 225 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2019 | 2277 | 0.090 |
Why?
|
| Anesthesia, Epidural | 2 | 2009 | 239 | 0.090 |
Why?
|
| Translocation, Genetic | 3 | 2000 | 1393 | 0.080 |
Why?
|
| Cohort Studies | 9 | 2023 | 41652 | 0.080 |
Why?
|
| Dental Scaling | 1 | 2009 | 109 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 903 | 0.080 |
Why?
|
| Anesthesia, Spinal | 2 | 2009 | 290 | 0.080 |
Why?
|
| Critical Illness | 4 | 2023 | 2746 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2185 | 0.080 |
Why?
|
| Graft vs Host Disease | 6 | 2017 | 3078 | 0.080 |
Why?
|
| Iohexol | 1 | 2010 | 205 | 0.080 |
Why?
|
| Procarbazine | 4 | 1997 | 172 | 0.080 |
Why?
|
| Lung | 4 | 2022 | 10031 | 0.080 |
Why?
|
| Mechlorethamine | 4 | 1997 | 129 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 1760 | 0.080 |
Why?
|
| Emergency Service, Hospital | 3 | 2023 | 7876 | 0.080 |
Why?
|
| Cladribine | 2 | 1998 | 34 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 691 | 0.080 |
Why?
|
| Anthracyclines | 1 | 2010 | 284 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 1755 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3849 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 15887 | 0.080 |
Why?
|
| Physicians | 2 | 2019 | 4587 | 0.070 |
Why?
|
| Dacarbazine | 4 | 2017 | 552 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2012 | 716 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2000 | 451 | 0.070 |
Why?
|
| Inflammation | 3 | 2023 | 10844 | 0.070 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 709 | 0.070 |
Why?
|
| Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2242 | 0.070 |
Why?
|
| Splenectomy | 4 | 1998 | 390 | 0.070 |
Why?
|
| Hospitals | 1 | 2021 | 3890 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 12969 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3616 | 0.070 |
Why?
|
| Analgesia, Obstetrical | 1 | 2009 | 175 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3655 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2020 | 5997 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6508 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1801 | 0.070 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 39226 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 2513 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 2969 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 459 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3278 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2014 | 1516 | 0.060 |
Why?
|
| Predictive Value of Tests | 7 | 2022 | 15403 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3926 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2015 | 2120 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2019 | 3286 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 3641 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2006 | 472 | 0.060 |
Why?
|
| Stomatitis | 1 | 1987 | 270 | 0.060 |
Why?
|
| Age Distribution | 4 | 2011 | 2865 | 0.060 |
Why?
|
| Models, Biological | 1 | 2020 | 9439 | 0.060 |
Why?
|
| Child | 11 | 2021 | 80510 | 0.060 |
Why?
|
| Actuarial Analysis | 3 | 1997 | 368 | 0.060 |
Why?
|
| Interferon Type I | 2 | 1985 | 567 | 0.060 |
Why?
|
| Patient Discharge | 3 | 2022 | 3466 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2023 | 3737 | 0.050 |
Why?
|
| Living Donors | 1 | 2008 | 645 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2019 | 4863 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 1990 | 1295 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 1946 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 1315 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2020 | 770 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2008 | 1332 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 11506 | 0.050 |
Why?
|
| Biopsy | 4 | 2010 | 6766 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 1788 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1985 | 297 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 1985 | 438 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 266 | 0.050 |
Why?
|
| Graft vs Tumor Effect | 2 | 1999 | 70 | 0.050 |
Why?
|
| Transients and Migrants | 1 | 2005 | 170 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2006 | 1494 | 0.050 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 2 | 2002 | 25 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 20125 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22230 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2019 | 13044 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5440 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2010 | 820 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2019 | 2112 | 0.050 |
Why?
|
| Genes, myc | 2 | 2000 | 392 | 0.050 |
Why?
|
| Bone Marrow | 6 | 1997 | 2919 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 30187 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 918 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 2014 | 641 | 0.050 |
Why?
|
| Multivariate Analysis | 7 | 2008 | 12060 | 0.050 |
Why?
|
| Medical Records | 1 | 2006 | 1409 | 0.050 |
Why?
|
| Medicare | 1 | 2019 | 6821 | 0.040 |
Why?
|
| Inappropriate Prescribing | 1 | 2023 | 211 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 15647 | 0.040 |
Why?
|
| Life Tables | 2 | 1998 | 366 | 0.040 |
Why?
|
| Interferon-alpha | 3 | 1999 | 910 | 0.040 |
Why?
|
| Leukocyte Count | 3 | 2021 | 1603 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 14645 | 0.040 |
Why?
|
| Infant, Newborn | 6 | 2017 | 26341 | 0.040 |
Why?
|
| Ohio | 1 | 2001 | 320 | 0.040 |
Why?
|
| Transplantation Conditioning | 3 | 2008 | 1635 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 419 | 0.040 |
Why?
|
| Traumatology | 1 | 2001 | 101 | 0.040 |
Why?
|
| PubMed | 1 | 2020 | 130 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2021 | 404 | 0.040 |
Why?
|
| Birth Weight | 2 | 2015 | 2122 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 113 | 0.040 |
Why?
|
| Lymphoma, T-Cell | 2 | 1999 | 308 | 0.040 |
Why?
|
| Maternal Mortality | 1 | 2022 | 311 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 1731 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 1985 | 1078 | 0.040 |
Why?
|
| Maternal Age | 1 | 2022 | 804 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2001 | 271 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2014 | 3854 | 0.040 |
Why?
|
| Utah | 1 | 2019 | 130 | 0.040 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 153 | 0.040 |
Why?
|
| Centrifugation | 1 | 2019 | 121 | 0.040 |
Why?
|
| Postal Service | 1 | 1979 | 96 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2001 | 416 | 0.040 |
Why?
|
| Pentostatin | 1 | 1998 | 26 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 416 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2229 | 0.040 |
Why?
|
| Catheters | 1 | 2021 | 426 | 0.040 |
Why?
|
| Autopsy | 1 | 2022 | 1012 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2021 | 361 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 247 | 0.040 |
Why?
|
| Quality of Life | 4 | 2023 | 13470 | 0.040 |
Why?
|
| Cause of Death | 2 | 2022 | 3710 | 0.040 |
Why?
|
| France | 1 | 2019 | 495 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 682 | 0.040 |
Why?
|
| Urinalysis | 1 | 2000 | 370 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2020 | 430 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2022 | 557 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3538 | 0.040 |
Why?
|
| Thrombin | 1 | 2021 | 603 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1999 | 322 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2000 | 338 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2019 | 163 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 713 | 0.040 |
Why?
|
| Lactation Disorders | 1 | 2017 | 14 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2021 | 3584 | 0.040 |
Why?
|
| Diagnostic Imaging | 3 | 2000 | 3527 | 0.040 |
Why?
|
| Gender Identity | 1 | 2023 | 767 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2020 | 412 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2019 | 236 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2023 | 1027 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2021 | 536 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2001 | 1049 | 0.030 |
Why?
|
| Sex Distribution | 2 | 1999 | 2268 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2001 | 494 | 0.030 |
Why?
|
| Medication Errors | 1 | 2023 | 786 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2015 | 2654 | 0.030 |
Why?
|
| Nurse's Role | 1 | 2018 | 187 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2000 | 526 | 0.030 |
Why?
|
| Contrast Media | 1 | 2010 | 5330 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2017 | 1834 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2017 | 570 | 0.030 |
Why?
|
| Vena Cava Filters | 1 | 2019 | 272 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1999 | 689 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1589 | 0.030 |
Why?
|
| Microvessels | 1 | 2020 | 589 | 0.030 |
Why?
|
| Gene Expression | 1 | 2008 | 7583 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1186 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 622 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 1999 | 1144 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2000 | 732 | 0.030 |
Why?
|
| Fetal Death | 1 | 2017 | 434 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2001 | 1776 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 2894 | 0.030 |
Why?
|
| Stockings, Compression | 1 | 2015 | 37 | 0.030 |
Why?
|
| Organization and Administration | 1 | 2014 | 54 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.030 |
Why?
|
| Necrosis | 1 | 2019 | 1613 | 0.030 |
Why?
|
| Chorionic Villi | 1 | 2015 | 53 | 0.030 |
Why?
|
| Phenotype | 2 | 2023 | 16707 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5368 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 646 | 0.030 |
Why?
|
| Interferons | 1 | 1998 | 714 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 2018 | 1527 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 805 | 0.030 |
Why?
|
| Carmustine | 4 | 1999 | 137 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2019 | 958 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 503 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2000 | 617 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2001 | 1369 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 2015 | 216 | 0.030 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 115 | 0.030 |
Why?
|
| Hematoma | 1 | 2018 | 766 | 0.030 |
Why?
|
| Piperazines | 1 | 2024 | 2546 | 0.030 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 134 | 0.030 |
Why?
|
| China | 1 | 2020 | 2387 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 791 | 0.030 |
Why?
|
| Sex Factors | 2 | 2019 | 10605 | 0.030 |
Why?
|
| Nuclear Energy | 1 | 2012 | 15 | 0.030 |
Why?
|
| Anemia, Refractory | 1 | 1992 | 17 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1993 | 108 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2001 | 1936 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 409 | 0.030 |
Why?
|
| Leptin | 1 | 2001 | 1597 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9521 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 888 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3504 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3200 | 0.030 |
Why?
|
| Telomerase | 1 | 2017 | 749 | 0.020 |
Why?
|
| Antithrombin Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1461 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2016 | 585 | 0.020 |
Why?
|
| Anemia, Sideroblastic | 1 | 1992 | 106 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20676 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2001 | 1845 | 0.020 |
Why?
|
| Canada | 1 | 1997 | 2119 | 0.020 |
Why?
|
| Hyperlipoproteinemias | 1 | 1991 | 19 | 0.020 |
Why?
|
| Serotonin | 1 | 2016 | 1047 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1999 | 6062 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3427 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 1885 | 0.020 |
Why?
|
| Infertility, Female | 1 | 2017 | 763 | 0.020 |
Why?
|
| Gestational Age | 2 | 2016 | 3615 | 0.020 |
Why?
|
| Karyotyping | 3 | 1999 | 1176 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1669 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 88 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 1997 | 1272 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 808 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 621 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1997 | 1536 | 0.020 |
Why?
|
| Leukapheresis | 1 | 1990 | 150 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2016 | 712 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 2009 | 70 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 5501 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2021 | 8062 | 0.020 |
Why?
|
| Arizona | 1 | 1989 | 108 | 0.020 |
Why?
|
| Mortality | 1 | 2021 | 2910 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2350 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2018 | 2112 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1999 | 1596 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2021 | 3051 | 0.020 |
Why?
|
| Immunophenotyping | 3 | 1999 | 1865 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2001 | 3687 | 0.020 |
Why?
|
| Inpatients | 1 | 2020 | 2565 | 0.020 |
Why?
|
| Age of Onset | 1 | 2016 | 3341 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 1644 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1999 | 1468 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1999 | 2883 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2020 | 2190 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4752 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 18065 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2008 | 433 | 0.020 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1988 | 179 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 2716 | 0.020 |
Why?
|
| Protons | 1 | 2012 | 1071 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 1238 | 0.020 |
Why?
|
| Length of Stay | 1 | 2001 | 6492 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 1997 | 11036 | 0.020 |
Why?
|
| Kidney | 1 | 2022 | 7073 | 0.020 |
Why?
|
| Remission Induction | 3 | 1999 | 2409 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 1988 | 493 | 0.020 |
Why?
|
| Prevalence | 2 | 2020 | 15833 | 0.020 |
Why?
|
| Risk | 1 | 1998 | 9600 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Logistic Models | 1 | 2001 | 13271 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1325 | 0.020 |
Why?
|
| Orchiectomy | 1 | 1988 | 465 | 0.020 |
Why?
|
| Germinal Center | 1 | 2008 | 379 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2269 | 0.020 |
Why?
|
| Pediatrics | 1 | 2001 | 3604 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 3318 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 2185 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 12520 | 0.020 |
Why?
|
| Siblings | 1 | 2009 | 828 | 0.010 |
Why?
|
| Phorbols | 1 | 1984 | 44 | 0.010 |
Why?
|
| Thyroxine | 1 | 1988 | 665 | 0.010 |
Why?
|
| Mass Screening | 1 | 2020 | 5448 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 1984 | 108 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1985 | 239 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2008 | 802 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 2005 | 508 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2004 | 284 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2687 | 0.010 |
Why?
|
| Nausea | 1 | 1985 | 679 | 0.010 |
Why?
|
| Leukemia | 2 | 1999 | 1523 | 0.010 |
Why?
|
| Palliative Care | 1 | 1997 | 3646 | 0.010 |
Why?
|
| Vomiting | 1 | 1985 | 646 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2009 | 1174 | 0.010 |
Why?
|
| Child, Preschool | 4 | 2011 | 42481 | 0.010 |
Why?
|
| Carcinogens | 1 | 1984 | 451 | 0.010 |
Why?
|
| Libido | 1 | 1982 | 123 | 0.010 |
Why?
|
| Smoking | 1 | 1998 | 9082 | 0.010 |
Why?
|
| Classification | 1 | 2002 | 128 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1988 | 1169 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1984 | 698 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 1726 | 0.010 |
Why?
|
| Cisplatin | 2 | 1999 | 1656 | 0.010 |
Why?
|
| Bacteriuria | 1 | 2000 | 102 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 10262 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1992 | 2284 | 0.010 |
Why?
|
| Infant | 3 | 2011 | 36377 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4109 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 5838 | 0.010 |
Why?
|
| Urine | 1 | 2000 | 362 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2000 | 438 | 0.010 |
Why?
|
| Lymph Nodes | 3 | 1997 | 3449 | 0.010 |
Why?
|
| Chromosome Aberrations | 2 | 1997 | 1776 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2001 | 6209 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 2630 | 0.010 |
Why?
|
| Prednisolone | 1 | 1999 | 323 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1991 | 2354 | 0.010 |
Why?
|
| Trisomy | 1 | 1999 | 259 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 455 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1998 | 99 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1982 | 665 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 1978 | 192 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2000 | 296 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1997 | 160 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1997 | 198 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1997 | 283 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 320 | 0.010 |
Why?
|
| Infertility | 1 | 1982 | 656 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1982 | 1181 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1984 | 2817 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1985 | 4884 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1997 | 498 | 0.010 |
Why?
|
| Menopause | 1 | 1982 | 1661 | 0.010 |
Why?
|
| Safety | 1 | 1999 | 1158 | 0.010 |
Why?
|
| Epirubicin | 1 | 1993 | 82 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1993 | 99 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1985 | 3210 | 0.010 |
Why?
|
| Animals | 3 | 2020 | 168721 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 679 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 614 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1997 | 616 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2001 | 1832 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8602 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1992 | 127 | 0.010 |
Why?
|
| Busulfan | 1 | 1993 | 264 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1985 | 4779 | 0.010 |
Why?
|
| Melphalan | 1 | 1993 | 425 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 697 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1991 | 384 | 0.010 |
Why?
|
| Hypertension | 1 | 2009 | 8627 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1999 | 2393 | 0.000 |
Why?
|
| Graft Survival | 1 | 2000 | 3897 | 0.000 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1999 | 1511 | 0.000 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1997 | 1534 | 0.000 |
Why?
|
| Radiography | 1 | 1999 | 6938 | 0.000 |
Why?
|
| Probability | 1 | 1993 | 2475 | 0.000 |
Why?
|
| Periodicals as Topic | 1 | 1979 | 1462 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 2839 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 860 | 0.000 |
Why?
|
| Stem Cells | 1 | 2000 | 3539 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 4208 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 2077 | 0.000 |
Why?
|
| Insulin | 1 | 2001 | 6598 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 1983 | 4904 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1991 | 1529 | 0.000 |
Why?
|
| Immunoglobulin D | 1 | 1985 | 55 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1985 | 116 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1993 | 1964 | 0.000 |
Why?
|
| Kidney Transplantation | 1 | 2000 | 4268 | 0.000 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1985 | 84 | 0.000 |
Why?
|
| Echocardiography | 1 | 1978 | 5042 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1988 | 1481 | 0.000 |
Why?
|
| Antibodies | 1 | 1991 | 2416 | 0.000 |
Why?
|
| Genotype | 1 | 1997 | 13024 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1983 | 355 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1985 | 1697 | 0.000 |
Why?
|
| Tyrosine | 1 | 1984 | 1427 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1984 | 1202 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 26283 | 0.000 |
Why?
|
| Amino Acids | 1 | 1984 | 1709 | 0.000 |
Why?
|
| Heart Murmurs | 1 | 1978 | 92 | 0.000 |
Why?
|
| Rupture, Spontaneous | 1 | 1978 | 359 | 0.000 |
Why?
|
| Protein Kinases | 1 | 1984 | 1611 | 0.000 |
Why?
|
| Uremia | 1 | 1978 | 202 | 0.000 |
Why?
|
| Kinetics | 1 | 1984 | 6261 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1985 | 2864 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1983 | 21062 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1983 | 2207 | 0.000 |
Why?
|
| Phosphorylation | 1 | 1984 | 8279 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 23702 | 0.000 |
Why?
|
| Cell Line | 1 | 1984 | 15541 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1978 | 1466 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1984 | 4046 | 0.000 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1978 | 1414 | 0.000 |
Why?
|